<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02351622</url>
  </required_header>
  <id_info>
    <org_study_id>ITP-Caffeic acid</org_study_id>
    <nct_id>NCT02351622</nct_id>
  </id_info>
  <brief_title>Caffeic Acid Tablets as a Second-line Therapy for ITP</brief_title>
  <official_title>A Multicentre Randomized Study of Caffeic Acid Tablets as a Second-line Therapy for the Treatment of Immune Thrombocytopenia (ITP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shandong Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qianfoshan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Anhui Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qingdao University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shandong University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are undertaking a multicentre, randomised controlled trial of 120 adults&#xD;
      with newly diagnosed ITP from 5 medical centers in China. Part of the participants are&#xD;
      randomly selected to receive caffeic acid tablets combining dexamethasone and the other part&#xD;
      are selected to receive high-dose dexamethasone treatment. Platelet count, bleeding and other&#xD;
      symptoms were evaluated before and after treatment. Adverse events are also recorded&#xD;
      throughout the study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All participants' platelet count will be monitored weekly. Response will be evaluated after&#xD;
      3, 6 and 12 months after treatment. If the participant did not get complete response or&#xD;
      response after 3 months, he would quit the trail.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proposed criteria for assessing response to ITP treatments</measure>
    <time_frame>3 months after treatment started</time_frame>
    <description>Complete response (CR)： A platelet count ≥ 100 * 10^9/L measured on two occasions &gt; 7 days apart and the absence of bleeding.&#xD;
Response (R)： A platelet count ≥ 30 * 10^9/L and a greater than two fold increase in platelet count from baseline measured on two occasions &gt; 7 days apart and the absence of bleeding.&#xD;
No response (NR)： A platelet count &lt; 30 * 10^9/L or a less than two fold increase in platelet count from baseline or the presence of bleeding. Platelet count must be measured on two occasions more than a day apart.&#xD;
Relapses: platelet count falls below 30×10^9/L or bleeding accrues after achieving R or CR.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">103</enrollment>
  <condition>Immune Thrombocytopenia</condition>
  <arm_group>
    <arm_group_label>caffeic acid tablet and dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration of caffeic acid tablet 0.3g three times per day for 1 year. Oral administration of dexamethasone 40 mg for four consecutive days then proceed another cycle 10 days later, 3 cycles in total.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo and dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral administration of placebo tablet 0.3g three times per day for 1 year. Oral administration of dexamethasone 40 mg for four consecutive days then proceed another cycle 10 days later, 3 cycles in total.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Caffeic acid</intervention_name>
    <description>Oral administration of caffeic acid tablet 0.3g three times per day for 1 year</description>
    <arm_group_label>caffeic acid tablet and dexamethasone</arm_group_label>
    <other_name>Caffeic acid tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Oral administration of dexamethasone 40 mg for four consecutive days then proceed another cycle 10 days later, 3 cycles in total.</description>
    <arm_group_label>Placebo and dexamethasone</arm_group_label>
    <arm_group_label>caffeic acid tablet and dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sugar pills manufactured to mimic caffeic acid tablet. Oral administration of placebo tablet 0.3g three times per day for 1 year.</description>
    <arm_group_label>Placebo and dexamethasone</arm_group_label>
    <other_name>Placebo tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Meet the diagnostic criteria for immune thrombocytopenia&#xD;
&#xD;
          2. Untreated hospitalized patients, may be male or female, between the ages of 18 ~ 80&#xD;
             years&#xD;
&#xD;
          3. To show a platelet count &lt;30 * 10^9/L, and with bleeding manifestations&#xD;
&#xD;
          4. Willing and able to sign written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Received chemotherapy or anticoagulants or other drugs affecting the platelet counts&#xD;
             within 3 months before the screening visit&#xD;
&#xD;
          2. Received second-line ITP-specific treatments (eg, cyclophosphamide, 6-mercaptopurine,&#xD;
             vincristine, vinblastine, etc) within 3 months before the screening visit&#xD;
&#xD;
          3. Received high-dose steroids or IVIG in the 3 weeks prior to the start of the study&#xD;
&#xD;
          4. Current HIV infection or hepatitis B virus or hepatitis C virus infections&#xD;
&#xD;
          5. Severe medical condition (lung, hepatic or renal disorder) other than chronic ITP.&#xD;
             Unstable or uncontrolled disease or condition related to or impacting cardiac function&#xD;
             (e.g., unstable angina, congestive heart failure, uncontrolled hypertension or cardiac&#xD;
             arrhythmia)&#xD;
&#xD;
          6. Female patients who are nursing or pregnant, who may be pregnant, or who contemplate&#xD;
             pregnancy during the study period&#xD;
&#xD;
          7. Have a known diagnosis of other autoimmune diseases, established in the medical&#xD;
             history and laboratory findings with positive results for the determination of&#xD;
             antinuclear antibodies, anti-cardiolipin antibodies, lupus anticoagulant or direct&#xD;
             Coombs test&#xD;
&#xD;
          8. Patients who are deemed unsuitable for the study by the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ming Hou, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shandong University, Qilu Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shandong University Qilu hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>January 21, 2015</study_first_submitted>
  <study_first_submitted_qc>January 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2015</study_first_posted>
  <last_update_submitted>April 18, 2016</last_update_submitted>
  <last_update_submitted_qc>April 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shandong University</investigator_affiliation>
    <investigator_full_name>Ming Hou</investigator_full_name>
    <investigator_title>Professor and Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Caffeic acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

